Current therapy of KRAS-mutant lung cancer
The review summarizes current therapeutic strategies for KRAS‑mutant lung adenocarcinoma and highlights that novel targeted agents, particularly covalent KRAS G12C inhibitors and combinations with downstream pathway blockade, offer promising avenues for tailored treatment.
KRAS mutations are the most frequent gain‑of‑function alterations in patients with lung adenocarcinoma (LADC) in the Western world. Although they have been identified decades ago, prior efforts to target KRAS signaling with single‑agent therapeutic approaches such as farnesyl transferase inhibitors, prenylation inhibition, impairment of KRAS downstream signaling, and synthetic lethality screens have been unsuccessful. Moreover, the role of KRAS oncogene in LADC is still not fully understood, and its prognostic and predictive impact with regards to the standard of care therapy remains controversial. Of note, KRAS‑related studies that included general non‑small cell lung cancer (NSCLC) population instead of LADC patients should be very carefully evaluated. Recently, however, comprehensive genomic profiling and wide‑spectrum analysis of other co‑occurring genetic alterations have identified unique therapeutic vulnerabilities. Novel targeted agents such as the covalent KRAS G12C inhibitors or the recently proposed combinatory approaches are some examples which may allow a tailored treatment for LADC patients harboring KRAS mutations. This review summarizes the current knowledge about the therapeutic approaches of KRAS‑mutated LADC and provides an update on the most recent advances in KRAS‑targeted anti‑cancer strategies, with a focus on potential clinical implications.
KRAS mutations are the most prevalent driver mutations in lung adenocarcinoma and represent a challenging therapeutic target; identifying effective treatments could significantly improve outcomes for this patient subset.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT